DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1×1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.
To schedule a 1×1 meeting with the Company, please contact your Wells Fargo institutional sales representative.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals.
This press release was published by a CLEAR® Verified individual.
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a…
Now Accepting Nomination Submissions for the Prestigious Annual AwardToronto, Ontario--(Newsfile Corp. - February 4, 2026)…
DRAPER, UTAH / ACCESS Newswire / February 4, 2026 / CenExel, a leading, wholly owned…
BOCA RATON, FL / ACCESS Newswire / February 4, 2026 / GridAI Technologies Corp. (Nasdaq:GRDX),…
Targeting Q1 2026 Launch, Subject to FDA ClearanceKey Highlights:Cartridge & Infusion Set Lots in Production:…
New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR…